Metabolic Peptide
Tirzepatide
Dual GIP/GLP-1 receptor agonist studied in glucose regulation models.
$100.00
Free shipping on orders over $300 · Same-day dispatch before 2PM EST
Select Option
Volume Discounts
Don't forget your reconstitution solution
Bacteriostatic Water 30mL
$14.99
Purchase Options
Lab Verified
HPLC-MS + endotoxin
Same-Day Ship
Orders by 2PM EST
Damage Coverage
Free replacement
Discreet Packaging
Plain outer box
Research Use Only
Not for human or veterinary consumption. For laboratory and in-vitro research purposes only.
Description
Tirzepatide is a dual GIP/GLP-1 receptor agonist investigated in research on insulin sensitivity and glycemic response.
Sold as a lyophilized peptide for non-clinical laboratory use.
Reconstitution
Reconstitute with bacteriostatic water in your preferred ratio. Store reconstituted vials refrigerated (2–8 °C) and use within recommended timeframes for your protocol.
Storage
Unreconstituted lyophilized powder stable at room temperature for short periods; refrigerate (2–8 °C) for long-term storage. Avoid repeat freeze/thaw cycles.
- Dose
- 10mg
- Purity
- ≥ 99%
- Form
- Lyophilized powder
- Storage
- Refrigerate after reconstitution
- Origin
- USA — synthesized & shipped domestically
- Testing
- HPLC-MS, MALDI, endotoxin screen
Research Overview
Tirzepatide is a synthetic 39-amino-acid peptide built as a dual agonist of the GIP and GLP-1 receptors. It is one of the most extensively characterized incretin-mimetic research peptides of the last decade, frequently used as a benchmark in comparative metabolic studies.
Its sequence is based on the native GIP backbone with strategic substitutions and a C20 fatty diacid moiety that prolongs circulating half-life in research models. Tirzepatide is supplied as a sterile lyophilized powder for in-vitro and laboratory use.
Mechanism of Action
Tirzepatide simultaneously engages GIP and GLP-1 receptors on pancreatic, adipose, and central nervous system tissues in research models. Co-activation has been studied for its effects on insulin secretion kinetics, glucagon suppression, and downstream signaling cascades.
Research Applications
- Dual incretin receptor pharmacology
- Glycemic response and beta-cell signaling studies
- Adipose and energy-balance research
- Comparative agonist potency assays
Study Highlights
Balanced dual agonism
Published in-vitro work has characterized tirzepatide's biased signaling profile, with notable activity at GIP receptors relative to native GIP and full agonism at GLP-1 receptors.
Long-acting design
The fatty acid moiety supports albumin binding, producing a research half-life suitable for once-weekly preclinical dosing models.
Reconstitution & Handling
Certificate of Analysis
Lot / Batch
QP-2025-7609
- Product
- Tirzepatide
- Manufacture date
- 2025-10-02
- Test date
- 2025-10-05
- Expiration
- 2028-10-02
- Appearance
- White to off-white lyophilized powder
- Identity
- Confirmed — matches reference standard
- Purity (HPLC)
- 99.70%
- Water content (KF)
- 1.30%
- Endotoxin (LAL)
- < 0.09 EU/mg
- Bioburden
- < 1 CFU / vial
- Analytical methods
- RP-HPLC, ESI-MS, MALDI-TOF, LAL endotoxin assay
- Released by
- QPUSA Quality Assurance Lab
